Adaptimmune Reports Second Quarter Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported its Q2 2021 results, highlighting an overall response rate of 39.3% in synovial sarcoma from its SPEARHEAD-1 trial. The company plans to submit a Biologics License Application (BLA) for afami-cel next year. Revenue for Q2 was $3.1 million, a significant increase from $0.5 million in Q2 2020, driven by collaboration activities. However, R&D expenses rose to $28.9 million, leading to a net loss of $39.1 million. The company expects to be funded into early 2023.
- Overall response rate of 39.3% in SPEARHEAD-1 trial for synovial sarcoma.
- Revenue increased to $3.1 million in Q2 2021 from $0.5 million in Q2 2020.
- Plans to file BLA for afami-cel next year.
- Cash and cash equivalents of $50.5 million as of June 30, 2021.
- Net loss of $39.1 million for Q2 2021, up from $29.9 million in Q2 2020.
- R&D expenses increased to $28.9 million in Q2 2021 from $20.5 million in Q2 2020.
- SPEARHEAD-1 data presented at ASCO with overall response rate of
- SURPASS trial data from 23 evaluable patients to be presented at ESMO -
- ADP-A2AFP Phase 1 trial data from 11 evaluable patients in Group 3/Expansion to be presented at ILCA -
- Financial guidance confirmed: funded into early 2023 -
- Conference call to be held today at 4:30 p.m. EDT (9:30 p.m. BST) -
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
“With the data presented at ASCO for afami-cel and our planned BLA filing next year, I am pleased with progress on our ‘2-2-5-2’ strategy,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “We will present data updates from our Phase 1 trials, SURPASS and ADP-A2AFP, at upcoming conferences and I am confident that Adaptimmune is well-placed to maintain its leadership position in cell therapies for cancer.”
Upcoming confirmed data updates
ADP-A2AFP Phase 1 Trial at ILCA
- On Sunday, September 5, 2021, Dr. Bruno Sangro of Clinica Universidad de Navarra will present data from Cohort 3 and the expansion phase of the Phase 1 trial of ADP-A2AFP in liver cancer during an oral presentation scheduled for 12:25 p.m. CET at the International Liver Cancer Association’s (ILCA) Annual Conference
- As of the April 5th data cut-off used for ILCA, 13 patients had received ADP-A2AFP in Cohort 3 and expansion, 11 patients were evaluable with at least one post-baseline scan
SURPASS Phase 1 Trial at ESMO
- The Company will present an update from its Phase 1 SURPASS trial in an e-poster at the European Society for Medical Oncology (ESMO) congress that will be available online September 16th
- As of the August 2nd data cut-off, 25 patients had received ADP-A2M4CD8, 23 patients had at least one post-baseline scan
- The trial continues to recruit in lung, gastroesophageal, head and neck, and bladder cancers – focus indications, for which there have been early signs of efficacy, including responses, with SPEAR T-cells targeting MAGE-A4
- Based on early data from patients with ovarian cancer treated in the trial, the Company is planning to add this as a focus indication to the SURPASS trial
SPEARHEAD-1 and afami-cel BLA
- As presented at ASCO 2021, the Company reported an overall response rate for patients with at least one scan (evaluated by RECIST 1.1 per investigator assessment) of
39.3% (13/33),41.4% (12/29) for synovial sarcoma, including two complete responses, and25.0% (1/4) for MRCLS from its Phase 2 SPEARHEAD-1 trial - Of the 29 patients with synovial sarcoma, the disease control rate (defined as either response or stable disease) was
86.2% (25/29 patients) with 2 complete responses and 10 partial responses - This data set is intended to support planned BLA filing next year
- Next data update planned at CTOS 2021
- The European Medicines Agency and the FDA have agreed to Adaptimmune’s pediatric investigational plans
- Working with key industry leaders to prepare for a successful commercial launch
- Adaptimmune has partnered with Agilent for the development, manufacturing, and supply of a companion diagnostic for the MAGE-A4 biomarker
- The Company is also working with Miltenyi Biotec for the process validation, manufacture, and supply of the lentiviral vector for use in the product for commercial launch
Further indications for next-gen SPEAR T-cell therapies
SURPASS-2
- Planning to initiate a Phase 2 clinical trial with ADP-A2M4CD8, SURPASS-2, in esophageal and esophagogastric junction cancers in the third quarter of 2021
Other early-stage programs
- The Company ceased enrollment in the Radiation Sub-Study of the afami-cel Phase 1 trial at the end of July. Five patients were treated in this sub-study and the Company plans to provide a data update at an upcoming congress
Corporate
- The Company received a development milestone payment of
$4.2 million in the three months ended June 30, 2021
Financial Results for the three and six months ended June 30, 2021
- Cash / liquidity position: As of June 30, 2021, Adaptimmune had cash and cash equivalents of
$50.5 million and Total Liquidity1 of$285.4 million . - Revenue: Revenue for the three and six months ended June 30, 2021 was
$3.1 million and$3.5 million , respectively, compared to$0.5 million and$1.3 million for the same periods in 2020. Revenue has increased primarily due to an increase in development activities under the Astellas Collaboration Agreement. - Research and development (R&D) expenses: R&D expenses for the three and six months ended June 30, 2021 were
$28.9 million and$53.4 million , respectively, compared to$20.5 million and$41.7 million for the same periods in 2020. R&D expenses increased due to an increase in the number of employees engaged in research and development, and increases in costs related to the development of a companion diagnostic assay and our Phase 2 clinical trial associated with ADP-A2M4CD8. These increases were partially offset by an increase in reimbursements receivable for research and development tax and expenditure credits. - General and administrative (G&A) expenses: G&A expenses for the three and six months ended June 30, 2021 were
$13.5 million and$27.4 million , respectively, compared to$10.3 million and$19.6 million for the same periods in 2020 due to increases in employee-related costs, share-based compensation expense, and professional fees. - Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three and six months ended June 30, 2021 was
$39.1 million and$76.8 million respectively ($(0.04) and$(0.08) per ordinary share), compared to$29.9 million and$58.0 million ($(0.04) and$(0.07) per ordinary share) for the same periods in 2020.
Financial Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023, as further detailed in the Company’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021, to be filed with the Securities and Exchange Commission following this earnings release.
Conference Call Information
The Company will host a live teleconference and webcast to provide additional details at 4:30 p.m. EDT (9:30 p.m. BST) today. A live webcast of the conference call and replay can be accessed at https://bit.ly/3zFas59. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial (833) 652-5917 (US or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (7867634).
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Total Liquidity (a non-GAAP financial measure)
Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):
| June 30, | December 31, | |||||
| 2021 | 2020 | |||||
| Cash and cash equivalents | $ | 50,453 | $ | 56,882 | ||
| Marketable securities - available-for-sale debt securities | 234,917 | 311,335 | ||||
| Total Liquidity | $ | 285,370 | $ | 368,217 | ||
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall liquidity, financial flexibility, capital structure and leverage.
Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data)
| Three months ended | Six months ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| Revenue | $ | 3,095 | $ | 502 | $ | 3,529 | $ | 1,263 | |||||||||
| Operating expenses | |||||||||||||||||
| Research and development | (28,868 | ) | (20,460 | ) | (53,374 | ) | (41,724 | ) | |||||||||
| General and administrative | (13,539 | ) | (10,295 | ) | (27,356 | ) | (19,556 | ) | |||||||||
| Total operating expenses | (42,407 | ) | (30,755 | ) | (80,730 | ) | (61,280 | ) | |||||||||
| Operating loss | (39,312 | ) | (30,253 | ) | (77,201 | ) | (60,017 | ) | |||||||||
| Interest income | 266 | 1,147 | 691 | 1,877 | |||||||||||||
| Other income (expense), net | 54 | (749 | ) | 53 | 188 | ||||||||||||
| Loss before income taxes | (38,992 | ) | (29,855 | ) | (76,457 | ) | (57,952 | ) | |||||||||
| Income taxes | (76 | ) | (25 | ) | (374 | ) | (95 | ) | |||||||||
| Net loss attributable to ordinary shareholders | $ | (39,068 | ) | $ | (29,880 | ) | $ | (76,831 | ) | $ | (58,047 | ) | |||||
| Net loss per ordinary share | |||||||||||||||||
| Basic and diluted | $ | (0.04 | ) | $ | (0.04 | ) | $ | (0.08 | ) | $ | (0.07 | ) | |||||
| Weighted average shares outstanding: | |||||||||||||||||
| Basic and diluted | 934,228,095 | 822,725,556 | 932,667,125 | 781,235,457 | |||||||||||||
Condensed Consolidated Balance Sheets
(unaudited, in thousands, except share data)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 50,453 | $ | 56,882 | ||||
| Marketable securities - available-for-sale debt securities | 234,917 | 311,335 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of | 2,158 | 139 | ||||||
| Other current assets and prepaid expenses | 49,816 | 29,796 | ||||||
| Total current assets | 337,344 | 398,152 | ||||||
| Restricted cash | 4,632 | 4,602 | ||||||
| Operating lease right-of-use assets, net of accumulated amortization | 17,772 | 18,880 | ||||||
| Property, plant and equipment, net of accumulated depreciation of | 28,663 | 27,778 | ||||||
| Intangibles, net of accumulated amortization | 1,382 | 1,730 | ||||||
| Total assets | $ | 389,793 | $ | 451,142 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 6,977 | $ | 6,389 | ||||
| Operating lease liabilities, current | 2,922 | 2,773 | ||||||
| Accrued expenses and other accrued liabilities | 26,606 | 27,079 | ||||||
| Deferred revenue, current | 4,911 | 2,832 | ||||||
| Total current liabilities | 41,416 | 39,073 | ||||||
| Operating lease liabilities, non-current | 19,723 | 20,938 | ||||||
| Deferred revenue, non-current | 50,048 | 49,260 | ||||||
| Other liabilities, non-current | 667 | 644 | ||||||
| Total liabilities | 111,854 | 109,915 | ||||||
| Stockholders’ equity | ||||||||
| Common stock - Ordinary shares par value | 1,336 | 1,325 | ||||||
| Additional paid in capital | 949,575 | 935,706 | ||||||
| Accumulated other comprehensive loss | (10,385 | ) | (10,048 | ) | ||||
| Accumulated deficit | (662,587 | ) | (585,756 | ) | ||||
| Total stockholders' equity | 277,939 | 341,227 | ||||||
| Total liabilities and stockholders’ equity | $ | 389,793 | $ | 451,142 | ||||
Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
| Six months ended | ||||||||
| June 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (76,831 | ) | $ | (58,047 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 2,879 | 3,583 | ||||||
| Share-based compensation expense | 10,783 | 4,072 | ||||||
| Unrealized foreign exchange gains | (267 | ) | (2,004 | ) | ||||
| Amortization on available-for-sale debt securities | 2,884 | 702 | ||||||
| Other | 1,401 | 480 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Increase in receivables and other operating assets | (21,457 | ) | (10,104 | ) | ||||
| Decrease in non-current operating assets | — | 615 | ||||||
| Increase in payables and other current liabilities | 663 | 3,571 | ||||||
| Increase in deferred revenue | 1,946 | 49,074 | ||||||
| Net cash used in operating activities | (77,999 | ) | (8,058 | ) | ||||
| Cash flows from investing activities | ||||||||
| Acquisition of property, plant and equipment | (2,924 | ) | (460 | ) | ||||
| Acquisition of intangibles | (143 | ) | (407 | ) | ||||
| Maturity or redemption of marketable securities | 154,465 | 39,931 | ||||||
| Investment in marketable securities | (81,958 | ) | (298,016 | ) | ||||
| Net cash provided by (used in) investing activities | 69,440 | (258,952 | ) | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of common stock from offerings, net of commissions and issuance costs | 2,519 | 334,388 | ||||||
| Proceeds from exercise of stock options | 578 | 5,075 | ||||||
| Net cash provided by financing activities | 3,097 | 339,463 | ||||||
| Effect of currency exchange rate changes on cash, cash equivalents and restricted cash | (937 | ) | (678 | ) | ||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (6,399 | ) | 71,775 | |||||
| Cash, cash equivalents and restricted cash at start of period | 61,484 | 54,908 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 55,085 | $ | 126,683 | ||||
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Corporate Affairs and Communications
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — VP, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com
FAQ
What is the overall response rate reported by Adaptimmune for the SPEARHEAD-1 trial?
What was Adaptimmune's revenue for Q2 2021?
When does Adaptimmune plan to file for BLA for afami-cel?
What is the net loss reported by Adaptimmune for Q2 2021?
How long is Adaptimmune funded for according to the latest financial guidance?
